AZ expanding Maryland biologics center; Valeant eyes securities buyback;

@FiercePharma: #FDA approves Purdue's abuse-resistant Hysingla, a hydrocodone pill aimed at knocking off Zohydro. Story | Follow @FiercePharma

@CarlyHFierce: #ICYMI yesterday - Themis, Institut Pasteur expand collaboration on solid PhI Chikungunya results. | Follow @CarlyHFierce

> AstraZeneca ($AZN) is socking $200 million-plus into expansions at its Frederick, MD biologics manufacturing center. Release

>Valeant Pharmaceuticals ($VRX) says it could buy back up to $2 billion worth of securities just days after losing a bid to acquire Allergan. Report

> The Washington Post calls Pfizer's ($PFE) failed bid for AstraZeneca the year's "biggest financial turkey." More

Medical Device News

@FierceMedDev: InfoBionic gets $17M to offer cloud-based cardiac monitoring. Story | Follow @FierceMedDev

@StacyALawrence: Second Sight IPO pops 122% in first day. That's 8th largest IPO pop this year in any sector. See my updated story. | Follow @StacyALawrence

@VarunSaxena2: Smith & Nephew closes U.S. facility, sells another in U.K. with 100+ to be laid off $SNN. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FierceDiagnostics: Illumina and bioMérieux to develop innovative sequencing system for infectious diseases. Article | Follow @EmilyWFierce

> Gates Foundation backs Ebola trials for plasma-based and other treatments. Article

> Tandem partners for open-source software to improve insulin pump data access. More

> Boston Scientific ordered to hand over $18.5M in vaginal mesh litigation. Story

Biotech News

@FierceBiotech: EuroBiotech Report: U.K. starts ambitious drug dev review, Onxeo to raise €41.6M, Galapagos mulls Nasdaq listing. More | Follow @FierceBiotech

@JohnCFierce: 5 of the top 10 biotech news stories of the year so far in FierceBiotech are on immuno-oncology. Oh, my. | Follow @JohnCFierce

@DamianFierce: $ABBV's hep C combo will be branded as Viekirax + Exviera (at least in Europe). More from the EMA | Follow @DamianFierce

> Beware sketchy biotechs with big plans for Ebola, SEC says. Article

> AbbVie gets an EU green light for its next-gen hep C treatment. More

> Purdue wins a pain pill approval with Zohydro in its crosshairs. News

And Finally... Bloomberg takes a look at the code names used during the Valeant-Allergan ($AGN)-Actavis ($ACT) takeover battle, including Valeant's "Project Olympus" and Actavis' "Project Fruit Basket." More